The Clorox Company (NYSE: CLX) has recently witnessed a downgrade to “Underweight” by analyst Andrea Teixeira at JP Morgan, causing ripples among investors. This shift, marked on April 17, 2026, comes at a time when the stock is priced at $104.58, which is notably close to the revised price target of $99. This decision raises questions about the company’s ability to navigate its current challenges effectively, prompting investors to reconsider their positions.
Recent Price Action
In recent trading sessions, CLX has shown a slight uptick, reflecting a change of $2.20, or approximately 2.15%. The stock’s current price sits at $104.58, yet it remains significantly below its 52-week high of $124.73, reflecting a decline of around 20.15%. On the downside, the stock has a 52-week low set at $31.27, illustrating substantial volatility over the past year. Trading volume has been robust, reaching 2.52 million shares recently, surpassing its average volume of around 2.22 million. This increased activity indicates heightened investor interest and potentially volatile sentiments within the market. Notably, CLX maintains a market capitalization of approximately $12.76 billion with a beta of 0.645, suggesting that it is less volatile than the broader market.
[chart type=’price’ value=’CLX’]
Historical Performance
When placing CLX’s recent performance within the broader market context, the stock has endured a challenging landscape. Over the past 30 days, Clorox shares have gained approximately 8.2%, slightly recovering from an earlier downtrend. However, the company’s quarterly performance paints a less optimistic picture, with a decline of about 8.25% over the last three months. Year-to-date, CLX is down approximately 31.55%, reflecting a severe downturn affected by various external and internal pressures. The stock experienced a weekly volatility rate of 2.26%, compared to a monthly volatility of 2.14%, indicating fluctuating investor sentiment and market uncertainty.
[chart type=’performance’ value=’CLX’]
Earnings Analysis
The latest earnings report, dated November 3, 2025, offers a mixed bag of insights. CLX reported earnings per share (EPS) of $0.85, surpassing analysts’ estimates of $0.818, leading to a surprise factor of approximately 3.91%. This marks a notable improvement compared to the previous quarter, where the company reported an EPS of $2.87 against an estimate of $2.20, yielding an impressive surprise of over 30%. The recent results, while better than anticipated, prompt further examination of the company’s long-term profitability as it grapples with a shift in consumer spending and competitive pressures.
[chart type=’income-bar-chart’ value=’CLX’]
Consensus Ratings
Analyst sentiment surrounding CLX has shifted significantly, reflecting the broader concerns in the market. Following the downgrade by JP Morgan, the analyst consensus reveals no “Buy” ratings, with 4 “Sell” and 9 “Hold” ratings among 13 analysts. The average price target stands at $111.77, signifying a potential upside from the current trading price, though the low-end forecast aligns with the recent downgrade to $99. This mixed consensus indicates a cautious outlook as investors weigh potential risks against opportunities.
[chart type=’analyst-ratings’ value=’CLX’]
Stock Grading or Fundamental View
The Stocks Telegraph grading score for The Clorox Company is currently at 54, suggesting that while the company has some solid fundamentals, significant concerns persist. This score indicates a moderate investment profile based on various financial metrics and market conditions. Investors looking for sector leadership or innovation might find Clorox’s current health less enticing amidst fluctuating consumer behavior and extensive market challenges.
[chart type=’st-cards’ value=’CLX’]
Conclusion
The Clorox Company appears to be in a precarious position, making it a noteworthy observation for investors. Those leaning towards a long-term growth outlook may want to tread carefully, given the company’s recent downgrade and operating challenges. While the latest earnings report shows a positive surprise, concerns about market conditions, coupled with a lack of bullish analyst ratings, may imply significant risks. Thus, this stock may best suit conservative investors who are equipped to monitor evolving market conditions closely. As Clorox navigates its next steps, it remains a company worth watching for any signs of improvement or further decline.